Sun Pharma Q1 Profit Hit by One-Off

  Published 10 months ago

Sun Pharma’s Q1 profit dropped due to an exceptional charge, though strong sales growth was seen across global markets.

  • Profit before exceptional items rose 16.6% YoY to Rs 3,990.8 crore; EBITDA grew 19.2% with a 31.1% margin.
  • India and US formulation sales grew 13.9% YoY each, together forming over 63% of total Q1 consolidated sales.
  • Global Innovative Medicines and RoW markets showed robust double-digit growth, supporting overall revenue momentum.

You might like these

Tejas Networks Soars on ₹1525 Crore BSNL 4G Order

Prime Focus Sees Big Investor Moves

Trent Q1 Profit Growth Slows Sharply

Royal Orchid Hotels Rises on New Property Launch in Solapur

India’s Forex Reserves Fall $1.18B

PNC Infratech Bridge Project Bihar

India's Coal Production Surges in May 2025

News that matters the most ⚡